Roughly 82 percent of Americans support requiring Medicare and insurance companies to cover the Alzheimer's treatments.

This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...

The Alzheimer's disease drug Kisunla will face major reimbursement challenges in the U.K. after the cost-effectiveness ...

Ladies and gentlemen, thank you for standing-by, and welcome to the Lilly Q3 2024 Earnings Call. [Operator Instructions] I ...

The company has two rising stars that could soon boost revenue considerably. The FDA approved Kisunla as a treatment for ...

Roche later made changes to the trial design, although the company said overall results support further testing.

People with schizophrenia often experience auditory hallucinations of voices that berate and bully them. New data suggests they may benefit from a type of behavioral therapy that uses digital avatars ...

ARIA-E was observed in 14 percent of patients who received a modified dosing regimen, compared to 24 percent of patients who received standard dosing.

Eli Lilly and Company disappointed with missed earnings, lower guidance. Click here for my review of LLY Q3 earnings and a ...

ABC News reports a 17.5% increase in asthma-related hospitalization in the three months after Flovent was discontinued and a 24.1% increase in the next three to six months. Other pharma news covers ...

Approved by the FDA in July to treat adults with early symptomatic Alzheimer’s disease, Eli Lilly’s Kisunla reduced the brain ...

Eli Lilly & Co. reported its results for the third quarter of 2024, with revenue up 20% y/y but failing to meet market ...